Literature DB >> 12576737

No priming of the immune response in newborn brown norway rats dosed with ovalbumin in the mouth.

C Madsen1, K Pilegaard.   

Abstract

BACKGROUND: Other researchers have reported that the specific immune response to subsequent antigen challenge is primed in newborn mice or rats dosed orally by gavage. We wanted to investigate if priming of a subsequent specific IgE response could be achieved by dosing newborn rats orally with ovalbumin and if this method could be used in an animal model for food allergy.
METHODS: Newborn Brown Norway rats were dosed with ovalbumin in the mouth (100 microg or 6 mg). As young adults, the animals were dosed by gavage for 35 days with 1 mg ovalbumin/day or once intraperitoneally with 100 microg. Control groups were dosed by gavage or intraperitoneally but not as neonates. Additionally, young adult rats were dosed with 1 mg ovalbumin/day in the mouth for 35 days. Sera from individual animals were analysed for specific IgE and specific IgG.
RESULTS: In all experiments with neonatal rats the specific IgE and IgG responses were decreased compared to the control groups, however, not always reaching statistical significance. A statistical significant decrease in the specific immune response was found in young adult rats dosed in the mouth as compared to by gavage.
CONCLUSIONS: Dosing Brown Norway rats with ovalbumin in the mouth as neonates do not prime the specific immune response. The decrease in immune response found in our experiments when dosing newborn animals in the mouth in opposition to the priming seen by others when dosing by intragastric intubation may be explained by a dissimilar antigen presentation when dosing includes both oral mucosa and gut. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576737     DOI: 10.1159/000068368

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  1 in total

Review 1.  Animal models of food allergy: opportunities and barriers.

Authors:  Scott McClain; Gary A Bannon
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.